April 2026
Neuroplasticity
What April 2026's 10 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research in April 2026 consistently found that various interventions (ketamine, ayahuasca, muscimol, and classic hallucinogens) promote neuroplasticity through mechanisms such as BDNF upregulation, synaptic scaling, and modulation of glutamatergic and GABAergic pathways, with effects observed in depression, schizophrenia, and Alzheimer's models. However, the evidence is largely preclinical or from small clinical studies, and the durability and optimal dosing of these neuroplasticity effects remain unclear.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets. 2026 | preclinical | Supports | Ketamine rescues chronic stress-induced presynaptic hypertrophy of somatostatin-expressing interneurons and excessive inhibition of pyramidal neurons in the mPFC, identifying a neuroplastic mechanism. | |
| The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. 2026 | narrative review | Supports | The review integrates evidence that glutamatergic dysregulation and impaired neuroplasticity are key mechanisms in depression, supporting a monoamine-glutamate continuum framework. | |
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Ayahuasca administration is associated with rapid reductions in suicidal ideation and depressive symptoms, attributed partly to neuroplasticity via BDNF upregulation and DMN modulation. |
| Psychedelics and Autism Therapy: A Review of Current Research and Future Directions 2026 | review | Supports | Psychedelics like LSD, psilocybin, and MDMA promote neuroplasticity via 5-HT2A receptor modulation, potentially improving social behavior and emotional regulation in ASD. | |
| A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals? 2026 | systematic review | 78 | Supports | Ketamine induces LTP and synaptic scaling, with antidepressant effects peaking at 24 hours and declining over 2-3 days; twice- versus thrice-weekly dosing yields different outcomes. |
| Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry 2026 | theoretical | Unclear | Proposes a cerebellar-centered framework for mental illness, suggesting therapies must restore sensory filtering, but does not directly report neuroplasticity findings. | |
| The non-classic psychedelic muscimol suppresses inflammatory signaling and promotes neuroplasticity in schizophrenia-derived human cortical spheroids and astroglia 2026 | preclinical | Supports | Muscimol suppresses inflammatory signaling and promotes neuroplasticity-associated transcriptional programs (e.g., NTRK2, ELK1) in schizophrenia-derived models. | |
| Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks — Including Life Between Lives and Transpersonal Hypnotherapy 2026 | review | Supports | Multiple altered states of consciousness modalities (including psychedelics) converge on neuroplasticity enhancement via BDNF and DMN modulation. | |
| Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. 2026 | review | Supports | Classic hallucinogens may restore mitochondrial integrity and enhance neuroplasticity via 5-HT2A and sigma-1 receptors, but clinical evidence is limited. | |
| Harnessing Neural Resiliency: A Comprehensive Review of Emerging Neuroplasticity Promoters and Their Clinical Efficacy in Depression Management 2026 | meta-analysis | 1504 | Supports | BDNF levels significantly increase after antidepressant treatment (effect size 0.62), correlating with clinical improvement, indicating enhanced neuroplasticity. |
Ketamine rescues chronic stress-induced presynaptic hypertrophy of somatostatin-expressing interneurons and excessive inhibition of pyramidal neurons in the mPFC, identifying a neuroplastic mechanism.
preclinical
The review integrates evidence that glutamatergic dysregulation and impaired neuroplasticity are key mechanisms in depression, supporting a monoamine-glutamate continuum framework.
narrative review
Ayahuasca administration is associated with rapid reductions in suicidal ideation and depressive symptoms, attributed partly to neuroplasticity via BDNF upregulation and DMN modulation.
systematic review Sample size: 5
Psychedelics like LSD, psilocybin, and MDMA promote neuroplasticity via 5-HT2A receptor modulation, potentially improving social behavior and emotional regulation in ASD.
review
Ketamine induces LTP and synaptic scaling, with antidepressant effects peaking at 24 hours and declining over 2-3 days; twice- versus thrice-weekly dosing yields different outcomes.
systematic review Sample size: 78
Proposes a cerebellar-centered framework for mental illness, suggesting therapies must restore sensory filtering, but does not directly report neuroplasticity findings.
theoretical
Muscimol suppresses inflammatory signaling and promotes neuroplasticity-associated transcriptional programs (e.g., NTRK2, ELK1) in schizophrenia-derived models.
preclinical
Multiple altered states of consciousness modalities (including psychedelics) converge on neuroplasticity enhancement via BDNF and DMN modulation.
review
Classic hallucinogens may restore mitochondrial integrity and enhance neuroplasticity via 5-HT2A and sigma-1 receptors, but clinical evidence is limited.
review
BDNF levels significantly increase after antidepressant treatment (effect size 0.62), correlating with clinical improvement, indicating enhanced neuroplasticity.
meta-analysis Sample size: 1504
Points of agreement
- Multiple studies (28190, 28990, 29154, 34074) report that interventions promoting neuroplasticity (e.g., ketamine, ayahuasca, muscimol) are associated with improvements in depression or related symptoms.
- BDNF upregulation is a common mechanism cited across ayahuasca (28190), psychedelic (27271), and antidepressant (34074) studies.
- Preclinical models (28802, 29154) consistently show that neuroplasticity changes occur at synaptic and molecular levels, including LTP and gene expression changes.
Conflicts
- The durability of neuroplasticity effects is inconsistent: ketamine effects peak at 24 hours and decline by 3 days (28990), while ayahuasca studies suggest rapid but not necessarily sustained effects (28190).
- The role of specific receptors varies: ketamine involves mu-opioid receptors (28802), while psychedelics primarily target 5-HT2A (27271, 28051), and muscimol acts via GABA-A (29154).
Gaps
- Long-term durability of neuroplasticity changes beyond a few days is not well studied (28990).
- Clinical evidence for neuroplasticity in Alzheimer's disease (28051) and autism (27271) remains largely preclinical or theoretical.
- Optimal dosing intervals for sustained neuroplasticity are unclear (28990).
- Most studies lack large-scale, randomized controlled trials with diverse populations (28190, 34074).